Delivery Order SPE2DR25D7009-SPE2DR26F8MRU
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $1,312.85 to AmerisourceBergen Drug Corp for the supply of Atropine 1 mg/10 mL syringes (10 mL). The contract is a firm fixed-price delivery order with an ultimate completion date of January 13, 2026, and was competitively awarded with no set-aside designation. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. This award represents a task order under AmerisourceBergen's parent company...
- The Defense Logistics Agency awarded a $4,690.10 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Atropine 1 mg/mL vials. This is a non-set-aside competitive award with an ultimate completion date of January 30, 2026, with performance based in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at up to...
- The Defense Logistics Agency awarded a $1,750.20 delivery order to AmerisourceBergen Drug Corp for Atropine 1 mg/ml vials, with an ultimate completion date of September 8, 2025. This non-set-aside, competitively awarded contract features firm fixed pricing and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a comprehensive...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order valued at $7,399.32 to AmerisourceBergen Drug Corp for the supply of Atropine 1 mg/ml vials. This competitively awarded, firm fixed-price contract has no set-aside designation and was issued on August 6, 2025, with an ultimate completion date of August 7, 2025. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $1...
- The Defense Logistics Agency awarded a delivery order valued at $3,576.02 to AmerisourceBergen Drug Corp for the supply of Atropine 1 mg/mL vials on January 29, 2026. The contract is competitively awarded with no set-aside designation and carries a firm fixed-price structure with a completion date of January 30, 2026. Performance will be executed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of Cencora, Inc., serves as a critical...
- The Defense Logistics Agency awarded a delivery order valued at $1,078.88 to AmerisourceBergen Drug Corp for the supply of Atropine 1 mg/10 ml syringes on January 29, 2026, with completion expected by January 30, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the awardee's facility in Conshohocken, Pennsylvania. Atropine is a critical emergency medical supply used in military and federal healthcare systems for treating...
- The U.S. Defense Logistics Agency (DLA) Troop Support Medical awarded a firm fixed price delivery order contract to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation, to provide Atropine 1 mg/mL vials. The $21,780.88 contract has a completion date of March 1, 2024 and does not include a set-aside designation. Amerisourcebergen Drug Corp, through its Corporate Office division in Conshohocken, Pennsylvania, is the prime contractor...
- The U.S. Department of Defense's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Atropine 1 mg/mL vials under a firm fixed-price contract valued at $2,111.43. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX, which carries a ceiling value of $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $1,843.93 delivery order for Atropine 0.4 mg/mL vials, with completion scheduled for December 12, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The contract will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order represents a continuation of AmerisourceBergen's critical role as a pharmaceutical supplier within the...
- The Defense Logistics Agency awarded a delivery order valued at $1,269.70 to AmerisourceBergen Drug Corp for the supply of Atropine 0.4 mg/mL vials. This award, issued on August 25, 2025, with an ultimate completion date of August 26, 2025, utilizes a firm fixed-price delivery order contract type with no set-aside designation. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, reflecting the company's role as a major pharmaceutical...
- SPE2DR25D7009Indefinite Delivery Contract
- SPE2DR25D7009-SPE2DR26F8MRUDelivery Order
The Defense Logistics Agency awarded a $4,536.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Atropine 1 mg/ml vials. This non-set-aside contract, which carries an ultimate completion date of January 30, 2026, represents a task order issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical. The DLA's Medical Supply Chain maintains this $999,999,999.00 IDC through December 2031 to support pharmaceutical and medical supply needs across military healthcare programs globally, encompassing a broad range of specialty medications, brand-name and generic drugs, vaccines, and critical medical devices. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, operates as a major pharmaceutical distributor serving federal medical procurement requirements, particularly for military and veteran healthcare systems. The company's delivery of Atropine—a critical emergency medication used for treating nerve agent exposure and certain cardiac conditions—reflects its role in supplying essential pharmaceutical commodities to support Defense Health Agency operations and other federal healthcare systems. The competitive award demonstrates AmerisourceBergen's continued capability to fulfill federal medical supply requirements across multiple therapeutic domains through DLA's comprehensive pharmaceutical support vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.5k | 1/28/26 |